CD5 and acute lymphoblastic leukemia: The results showed that fratricide-resistant FHVH-derived CD5/CD7 bispecific CAR-T cells showed potent antitumor activity to Jurkat, CCRF-CEM, MOLT-4, and SUP-T1 cell lines in vitro and CCRF-CEM T-ALL mouse model in vivo, it provided the possibility to the populations with antigen heterogeneous (68).